NO20084821L - Formuleringer og metoder for celleimaging og terapi - Google Patents

Formuleringer og metoder for celleimaging og terapi

Info

Publication number
NO20084821L
NO20084821L NO20084821A NO20084821A NO20084821L NO 20084821 L NO20084821 L NO 20084821L NO 20084821 A NO20084821 A NO 20084821A NO 20084821 A NO20084821 A NO 20084821A NO 20084821 L NO20084821 L NO 20084821L
Authority
NO
Norway
Prior art keywords
methods
cell imaging
therapy formulations
imaging
formulations
Prior art date
Application number
NO20084821A
Other languages
English (en)
Other versions
NO341574B1 (no
Inventor
Dong-Fang Yu
Saady Kohanim
David J Yang
Chang Sok Oh
Ali Azhdarinia
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO20084821L publication Critical patent/NO20084821L/no
Publication of NO341574B1 publication Critical patent/NO341574B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår generelt feltene kjemi og radionuklid-avbildning. Mer spesielt angår den preparater, sett og metoder for avbildning og terapi som involverer N4-forbindelser og derivater.
NO20084821A 2006-04-19 2008-11-18 Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode. NO341574B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74514806P 2006-04-19 2006-04-19
PCT/US2006/016784 WO2007120153A1 (en) 2006-04-19 2006-05-04 Compositions and methods for cellular imaging and therapy

Publications (2)

Publication Number Publication Date
NO20084821L true NO20084821L (no) 2009-01-16
NO341574B1 NO341574B1 (no) 2017-12-04

Family

ID=38609808

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084821A NO341574B1 (no) 2006-04-19 2008-11-18 Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode.

Country Status (13)

Country Link
EP (1) EP2013221B1 (no)
JP (1) JP2009534381A (no)
KR (2) KR20090014164A (no)
CN (1) CN101516899B (no)
AU (1) AU2006342202C1 (no)
BR (1) BRPI0621580B8 (no)
CA (1) CA2649869C (no)
DK (1) DK2013221T3 (no)
ES (1) ES2544244T3 (no)
HK (1) HK1123306A1 (no)
IL (1) IL194826A (no)
NO (1) NO341574B1 (no)
WO (1) WO2007120153A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
WO2015152128A1 (ja) * 2014-03-31 2015-10-08 長瀬産業株式会社 アミノ酸前駆体、アミノ酸およびその製造方法、ならびに該アミノ酸を用いたｐｅｔ診断用トレーサー
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
CN110062633A (zh) * 2016-11-30 2019-07-26 迪美公司 酪氨酸衍生物以及包含所述酪氨酸衍生物的组合物
EA202090116A1 (ru) * 2017-07-18 2020-05-14 ВИРИФАРМ ЭНТЕРПРАЙЗЕС, ЭлЭлСи Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
CN117088825A (zh) * 2023-10-12 2023-11-21 成都威斯津生物医药科技有限公司 一种可离子化脂质、含该可离子化脂质的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5684149A (en) * 1993-01-22 1997-11-04 Research Foundation Of State University Of New York Metal complexes for promoting catalytic cleavage of RNA by transesterification
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
EP1140864A2 (en) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
ES2221903T3 (es) * 2000-05-12 2005-01-16 University Hospital Agentes pro-quelantes para la preparacion de moleculas marcadas con metales radiactivos que tienen propiedades biologicas mejoradas.
CA2419631A1 (en) * 2000-09-29 2002-04-04 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
EP1583564B1 (en) * 2003-01-13 2009-07-01 Bracco Imaging S.p.A Improved linkers for radiopharmaceutical compounds
CN101137398B (zh) * 2005-01-05 2012-07-04 得克萨斯大学体系董事会 用于双重显像和放射化疗的缀合物：组合物、生产和应用

Also Published As

Publication number Publication date
KR20140099557A (ko) 2014-08-12
EP2013221A1 (en) 2009-01-14
BRPI0621580B1 (pt) 2021-05-11
HK1123306A1 (en) 2009-06-12
DK2013221T3 (en) 2015-09-28
BRPI0621580B8 (pt) 2021-05-25
IL194826A0 (en) 2009-08-03
CN101516899B (zh) 2016-07-06
EP2013221A4 (en) 2010-12-15
BRPI0621580A2 (pt) 2011-05-10
JP2009534381A (ja) 2009-09-24
CA2649869C (en) 2014-11-18
AU2006342202C1 (en) 2013-09-26
EP2013221B1 (en) 2015-06-24
IL194826A (en) 2013-08-29
AU2006342202A1 (en) 2007-10-25
KR20090014164A (ko) 2009-02-06
CN101516899A (zh) 2009-08-26
CA2649869A1 (en) 2007-10-25
WO2007120153A1 (en) 2007-10-25
ES2544244T3 (es) 2015-08-28
AU2006342202B2 (en) 2013-03-07
NO341574B1 (no) 2017-12-04
KR101653182B1 (ko) 2016-09-01

Similar Documents

Publication Publication Date Title
NO20084821L (no) Formuleringer og metoder for celleimaging og terapi
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
NO20090596L (no) Antivirale fosfinatforbindelser
NO20090628L (no) Pyridizinon derivativater
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
EA201170521A1 (ru) Новые соединения
EA200700225A1 (ru) Аналоги тетрапептида
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
GEP20094784B (en) Sustained release pharmaceutical formulations
EA200900959A1 (ru) Ингибиторы мек
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
EA201070247A1 (ru) Ингибиторы протеасом
SE0301700D0 (sv) Novel compounds
DK1893196T3 (da) Diarylhydantoin-forbindelse
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THE BOARD OF REGENTS OF THE UNIVERSITY OF TE, US